Bankers are cautiously optimistic about the prospects for equity issuance from biotechnology companies, even though the sector's first three initial public offerings of the year were forced to slash their issue prices.

Although the number of new listings may be limited, bankers agree that the environment for secondary issues should improve. Last year saw many biotechnology companies pull their flotation plans because of a lack of interest from investors.